Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-... by Gudrun Piringer, Gudrun Piringer, Gudrun Piringer, Jörn Decker, Vera Trommet, Thomas Kühr, Thomas Kühr, Sonja Heibl, Sonja Heibl, Konrad Dörfler, Josef Thaler, Josef Thaler

Get full text

Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer – a retrospective analysis by Gudrun Piringer, Gudrun Piringer, Gudrun Piringer, Florian Ponholzer, Josef Thaler, Josef Thaler, Thomas Bachleitner-Hofmann, Holger Rumpold, Holger Rumpold, Alexander de Vries, Lukas Weiss, Lukas Weiss, Richard Greil, Richard Greil, Michael Gnant, Dietmar Öfner

Get full text

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study by Gudrun Piringer, Gudrun Piringer, Thomas Gruenberger, Josef Thaler, Josef Thaler, Irene Kührer, Klaus Kaczirek, Friedrich Längle, Istvan Viragos-Toth, Arno Amann, Wolfgang Eisterer, Reinhold Függer, Johannes Andel, Angelika Pichler, Judith Stift, Lidija Sölkner, Michael Gnant, Dietmar Öfner

Get full text

Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment by Bernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, Gudrun Piringer, Georg Schreil, Jörn Decker, Karl J. Aichberger, Patrick Kirchweger, Josef Thaler, Andreas Petzer, Clemens A. Schmitt, Gerald W. Prager, Holger Rumpold

Get full text